Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 19, 2017
What are the generic sources for minocycline hydrochloride and what is the scope of minocycline hydrochloride freedom to operate?
Minocycline hydrochloride is the generic ingredient in seven branded drugs marketed by Impax Labs, Medicis, Zydus Worldwide, Mylan Pharms Inc, Triax Pharms, Sun Pharm Inds, Sun Pharm Inds Ltd, Sandoz, Impax Labs Inc, Lupin Ltd, Par Pharm, Dr Reddys Labs Ltd, Lederle, Rempex Pharms Inc, Precision Dermat, Alkem Labs Ltd, Torrent Pharma Inc, Aurobindo Pharma Ltd, Watson Labs, Cnty Line Pharms, Sun Pharm Inds Inc, Aurobindo Pharma, Watson Labs Teva, Orapharma, Barr Labs Inc, and Sidmak Labs India, and is included in thirty-three NDAs. There are thirteen patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.| Tradenames: | 7 |
| Patents: | 13 |
| Applicants: | 26 |
| NDAs: | 33 |
| Drug Master File Entries: see list | 13 |
| Suppliers / Packagers: see list | 49 |
| Bulk Api Vendors: see list | 45 |
| Clinical Trials: see list | 2,415 |
| Patent Applications: see list | 2,520 |
| Therapeutic Class: | Dental and Oral Agents |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | minocycline hydrochloride at DailyMed |
| Ingredient-type | Tetracyclines |
| Drug Class | Tetracycline-class Drug |
| Applicant | Application No. | Strength | Dosage Form |
| ► Subscribe | ► Subscribe | EQ 45MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| ► Subscribe | ► Subscribe | EQ 135MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| ► Subscribe | ► Subscribe | EQ 115MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Torrent Pharma Inc | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | CAPSULE;ORAL | 065062-003 | Nov 30, 2000 | AB | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Sun Pharm Inds Inc | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | CAPSULE;ORAL | 090867-003 | May 13, 2013 | AB | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Torrent Pharma Inc | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | CAPSULE;ORAL | 065062-001 | Nov 30, 2000 | AB | RX | No | No | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Zydus Worldwide | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | CAPSULE;ORAL | 063009-001 | Mar 2, 1992 | AB | RX | No | Yes | ► Subscribe | ► Subscribe | ► Subscribe | |||||||||||||||||
Orapharma | ARESTIN | minocycline hydrochloride | POWDER, EXTENDED RELEASE;DENTAL | 050781-001 | Feb 16, 2001 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011143503 | ► Subscribe | |||||||||||||||||||||||||||
| European Patent Office | 2568987 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 2568987 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 6025712 | ► Subscribe | |||||||||||||||||||||||||||
| Singapore | 185513 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,362 others who get our Drug Patent Expiration Alerts:
